Hi Ray,
You know Revlimid is not approved for MDS in EU because there might be a small increased risk for AML especially in the non-responders.
http://www.ema.europa.eu/humandocs/P...29408908en.pdf
Revlimid is OK for patients with the 5q- chromosome aberration and 75% of them have a very good response. I have read about patients who were free from symptoms more than 5 years when they got Revlimid.
Then a proportion of the RA paients have a positive respons to ATG treatment - som of these patients are free from symptoms during many years and seem to be much like AA patients.
The reseachers will perhaps find other groups of MDS who will respond to a special treatment.
Then we ought to know more about the best dosing - lower doses for longer time is perhaps better that short treatment during 3, 5 or 7 days in a 28 day period. Patients with CML take Gleevec every day and patients with Myeloma take Revlimid every day.
You will hopefully be able to "review and carefully consider options" during many years!
Kind regards
Birgitta-A